Navigation Links
Roche puts in an Application to Use Herceptin for Treatment in Her-2 positive breast cancer

Roche has made a formal application to the European Medicines Agency (EMEA) to enable the use of Herceptin (trastuzumab) as a viable treatment// for advanced HER2-positive and hormone receptor-positive breast cancer.

The application follows the encouragement received from the international TAnDEM study which showed that the use of Herceptin enhances the median progression-free survival from 2.4 months to 4.8 months.

HER2-positive breast cancer affects almost 20 to 30 percent of women with breast cancer, and is a galloping form of the disease that demands immediate attention due to the tumors growing at a rapid rate with a greater chance of relapse.

Eduard Holdener, Global Head of Roche Pharma Development said, "The results from the TAnDEM study show once again that Herceptin should be the backbone for all HER2-positive breast cancer patients -- it consistently benefits patients regardless of whether it is given in the early- or advanced-stage settings, or whether it is in combination with chemotherapy, hormonal therapy, or as a single agent. This combination offers a new treatment regimen for patients who suffer from a particularly aggressive form of breast cancer, and we are pleased to have been able to progress this application so quickly."
'"/>




Page: 1

Related medicine news :

1. FDA Imposes New Restrictions On Roches Accutane
2. Roche confirms Tamiflu production talks in US
3. Roche offers HIV drug expertise to poor nations
4. Roche Commits More Antiviral Pills To Asia For Bird Flu
5. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
6. Roche Rolls Out Lung Cancer Drug In India
7. New Lung Cancer Drug Launched By Roche Pharmaceutical
8. Roche Calls For Re-Examination Of Tarceva Data By EU Authorities
9. NICE Gives the Final ‘NO’ to Roche’s Tarcva
10. Prostate Cancer Can Be Treated By Application Of LASER Technology
11. Varied Applications of Adult Stem Cells to Treat Host of Disorders in Human
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix announced on Wednesday that ... an emergency medicine professional association, to support the organization's newly established physician group ... of Emergency Medicine, or AAEM, seeks to empower emergency physicians to control their ...
(Date:2/10/2016)... ... ... Emergency rooms provide emergency care to stabilize critical health issues, but emergency dental ... at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, dentist ... include:, , Avulsed or knocked-out teeth , Dislodged ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of Barron Family Dental ... dental patients and families in the North Metro Denver area. The new dental practice ... cosmetic dentistry, and all in the most relaxing environment. , While some dental visits ...
(Date:2/10/2016)... IN (PRWEB) , ... February 10, 2016 , ... ... benefits advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing ... has seven other locations throughout the Southeast, from Orlando to Huntsville and in ...
(Date:2/10/2016)... ... 10, 2016 , ... Armune BioScience signed a definitive agreement with ... service centers across the country. Launched in April of 2015, Apifiny is the only ... cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Feb. 10, 2016  LexisNexis® Risk Solutions, a ... announced the launch of LexisNexis Provider Performance ... helps improve and optimize the quality and efficiency ... using severity-adjusted scores. By measuring provider performance through ... to deliver better outcomes, improve the patient experience ...
(Date:2/10/2016)... CORAL SPRINGS, Florida , February 10, 2016 ... Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS ) and Celldex Therapeutics, ... Medivation, Inc. (NASDAQ: MDVN ), Adamas Pharmaceuticals, Inc. (NASDAQ: ... ). --> Today,s latest Orphan Drug Designations become ... granted by the FDA to novel drugs and biologics which ...
(Date:2/10/2016)... , Feb. 10, 2016 /PRNewswire/ - The President ... has announced the release of an anti-radiation product ... a revolutionary breakthrough in the treatment of cancer ... exposure. It will assist in the healing of ... It will also protect only the healthy cells ...
Breaking Medicine Technology: